Terms: = Lung cancer AND EZR, CVIL, 7430, ENSG00000092820, P15311, MGC1584, FLJ26216, DKFZp762H157, CVL
38 results:
1. Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.
Dong W; Zhuge J; Yu P; Liu K; Yang M; Wang H
Medicine (Baltimore); 2023 Dec; 102(51):e36591. PubMed ID: 38134118
[TBL] [Abstract] [Full Text] [Related]
2. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
[TBL] [Abstract] [Full Text] [Related]
3. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
[TBL] [Abstract] [Full Text] [Related]
4. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract] [Full Text] [Related]
5. Silencing lncRNA ezr‑AS1 induces apoptosis and attenuates the malignant properties of lung adenocarcinoma cells.
Yu X; Wu L; Lu Z; Zhang J; Zhou Y
Acta Biochim Pol; 2023 Sep; 70(3):713-719. PubMed ID: 37722090
[TBL] [Abstract] [Full Text] [Related]
6. Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma.
Li X; Chen J; Zhang C; Han Z; Zheng X; Cao D
BMC Pulm Med; 2023 Sep; 23(1):339. PubMed ID: 37697337
[TBL] [Abstract] [Full Text] [Related]
7. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
[TBL] [Abstract] [Full Text] [Related]
8. TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating ezr.
Xie A; Xu X; Kuang P; Zhang L; Yu F
Cell Death Dis; 2021 Aug; 12(9):804. PubMed ID: 34429402
[TBL] [Abstract] [Full Text] [Related]
9. Development and Validation of Machine Learning-based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts.
Chen K; Nie Y; Park S; Zhang K; Zhang Y; Liu Y; Hui B; Zhou L; Wang X; Qi Q; Li H; Kang G; Huang Y; Chen Y; Liu J; Cui J; Li M; Park IK; Kang CH; Shen H; Yang Y; Guan T; Zhang Y; Yang F; Kim YT; Wang J
Clin Cancer Res; 2021 Apr; 27(8):2255-2265. PubMed ID: 33627492
[TBL] [Abstract] [Full Text] [Related]
10. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract] [Full Text] [Related]
11. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas.
Qin J; Chen B; Li C; Yan J; Lu H
Cancer Genet; 2021 Jan; 250-251():12-19. PubMed ID: 33217678
[TBL] [Abstract] [Full Text] [Related]
12. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract] [Full Text] [Related]
13. [Increases in mRNA and Protein Levels of the Genes for the Actin-Binding Proteins Profilin, Fascin, and ezrin Promote Metastasis in Non-Small Cell lung cancer].
Kolegova ES; Kakurina GV; Kostromitskiy DN; Dobrodeev AY; Kondakova IV
Mol Biol (Mosk); 2020; 54(2):285-292. PubMed ID: 32392198
[TBL] [Abstract] [Full Text] [Related]
14. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with lung cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract] [Full Text] [Related]
15. Regulation of breast cancer resistance protein and P-glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines.
Yano K; Okabe C; Fujii K; Kato Y; Ogihara T
J Pharm Pharmacol; 2020 Apr; 72(4):575-582. PubMed ID: 31975441
[TBL] [Abstract] [Full Text] [Related]
16. lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis.
Abdel-Rahman O
Int J Clin Oncol; 2020 May; 25(5):885-891. PubMed ID: 31919692
[TBL] [Abstract] [Full Text] [Related]
17. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract] [Full Text] [Related]
18. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell lung Carcinoma: the ROSING Study.
Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; Mancheño N; Juan O; Sanz J; Gonzalez-Larriba JL; Atienza-Cuevas L; Arriola-Arellano E; Abdulkader I; Garcia-Gonzalez J; Camacho C; Rodriguez-Abreu D; Teixido C; Reguart N; Gonzalez-Piñeiro A; Lazaro-Quintela M; Lozano MD; Gurpide A; Gomez-Roman J; Lopez-Brea M; Pijuan L; Salido M; Arriola E; Company A; Insa A; Esteban-Rodriguez I; Saiz M; Azkona E; Alvarez R; Artal A; Plaza ML; Aguiar D; Enguita AB; Benito A; Paz-Ares L; Garrido P; Lopez-Rios F
J Thorac Oncol; 2019 Dec; 14(12):2120-2132. PubMed ID: 31349061
[TBL] [Abstract] [Full Text] [Related]
19. Different Types of
He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
[No Abstract] [Full Text] [Related]
20. The Prefectural Participation Rates of lung cancer Screening Had a Negative Correlation with the lung cancer Mortality Rates.
Sagawa M; Machii R; Nakayama T; Sugawara T; Ishibashi N; Mitomo H; Kondo T; Tabata T
Asian Pac J Cancer Prev; 2019 Mar; 20(3):855-861. PubMed ID: 30912404
[TBL] [Abstract] [Full Text] [Related]
[Next]
